MaxCyte Inc (MXCT) Ord USD0.01 (DI)

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
MaxCyte signs SPL deal with TG Therapeutics
12 February 2025 10:21
(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmaceutical company access to its 'Flow...
-
MaxCyte announces acquisition of SeQure Dx
30 January 2025 16:43
(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services for cell and gene therapies, in a move aimed at...
-
MaxCyte flags full-year revenue at top end of expectations
13 January 2025 14:34
(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quarter to range between $8.3m and $8.5m, up from $7.2m in the...
-
MaxCyte upgrades revenue guidance after operational review
9 December 2024 08:55
(Sharecast News) - Cell engineering technology specialist MaxCyte announced upgraded revenue guidance on Monday, following an operational review under its new chief executive officer Maher Masoud.
-
MaxCyte appoints new chief commercial officer
10 October 2024 13:23
(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Ali Soleymannezhad as its new chief commercial officer on Thursday, effective from 11 September.
-
MaxCyte enters licence agreement with Kamau Therapeutics
16 September 2024 11:22
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-stage firm specialising in stem cell gene correction...
-
MaxCyte reports solid second-quarter performance
7 August 2024 12:36
(Sharecast News) - Cell engineering company MaxCyte reported a robust financial performance for its second quarter on Wednesday, with total revenue reaching $10.4m, a 15% increase compared to the same period...
-
MaxCyte reports strong first quarter
8 May 2024 12:45
(Sharecast News) - MaxCyte reported total first-quarter revenue of $11.3m in an update on Wednesday, making for a 32% increase compared to the same period in 2023.
-
MaxCyte reports strong fourth quarter as full-year revenues fall
13 March 2024 12:04
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.
-
MaxCyte flags lower 2023 revenue, flat 2024 growth
5 March 2024 13:01
(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.
-
MaxCyte flags uptick in total fourth-quarter revenue
9 January 2024 08:55
(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.
-
Maher Masoud starts as MaxCyte president, CEO
2 January 2024 11:25
(Sharecast News) - MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.
Company announcements Announcements
-
Holding(s) in Company
19 February 2025 15:23
Maxcyte (DI)
-
Holding(s) in Company
14 February 2025 17:05
Maxcyte (DI)
-
Holding(s) in Company
13 February 2025 16:12
Maxcyte (DI)
-
Holding(s) in Company
13 February 2025 14:52
Maxcyte (DI)
-
Strategic Platform License with TG Therapeutics
12 February 2025 07:00
Maxcyte (DI)
-
Notice of Results
7 February 2025 07:00
Maxcyte (DI)
-
Total Voting Rights
4 February 2025 07:00
Maxcyte (DI)
-
Exercise of options and PDMR dealing
31 January 2025 15:18
Maxcyte (DI)
-
MaxCyte® Acquires SeQure Dx
30 January 2025 07:00
Maxcyte (DI)
-
Holding(s) in Company
29 January 2025 15:05
Maxcyte (DI)
-
Holding(s) in Company
22 January 2025 14:25
Maxcyte (DI)
-
Holding(s) in Company
21 January 2025 09:13
Maxcyte (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.